Literature DB >> 18987184

Folate deficiency induces in vitro and mouse brain region-specific downregulation of leucine carboxyl methyltransferase-1 and protein phosphatase 2A B(alpha) subunit expression that correlate with enhanced tau phosphorylation.

Jean-Marie Sontag1, Viyada Nunbhakdi-Craig, Lisa Montgomery, Erland Arning, Teodoro Bottiglieri, Estelle Sontag.   

Abstract

Altered folate homeostasis is associated with many clinical and pathological manifestations in the CNS. Notably, folate-mediated one-carbon metabolism is essential for methyltransferase-dependent cellular methylation reactions. Biogenesis of protein phosphatase 2A (PP2A) holoenzyme containing the regulatory B(alpha) subunit, a major brain tau phosphatase, is controlled by methylation. Here, we show that folate deprivation in neuroblastoma cells induces downregulation of PP2A leucine carboxyl methyltransferase-1 (LCMT-1) expression, resulting in progressive accumulation of newly synthesized demethylated PP2A pools, concomitant loss of B(alpha), and ultimately cell death. These effects are further accentuated by overexpression of PP2A methylesterase (PME-1) but cannot be rescued by PME-1 knockdown. Overexpression of either LCMT-1 or B(alpha) is sufficient to protect cells against the accumulation of demethylated PP2A, increased tau phosphorylation, and cell death induced by folate starvation. Conversely, knockdown of either protein accelerates folate deficiency-evoked cell toxicity. Significantly, mice maintained for 2 months on low-folate or folate-deficient diets have brain-region-specific alterations in metabolites of the methylation pathway. Those are associated with downregulation of LCMT-1, methylated PP2A, and B(alpha) expression and enhanced tau phosphorylation in susceptible brain regions. Our studies provide novel mechanistic insights into the regulation of PP2A methylation and tau. They establish LCMT-1- and B(alpha)-containing PP2A holoenzymes as key mediators of the role of folate in the brain. Our results suggest that counteracting the neuronal loss of LCMT-1 and B(alpha) could be beneficial for all tauopathies and folate-dependent disorders of the CNS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18987184      PMCID: PMC2688404          DOI: 10.1523/JNEUROSCI.2816-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  45 in total

1.  A specific protein carboxyl methylesterase that demethylates phosphoprotein phosphatase 2A in bovine brain.

Authors:  J Lee; Y Chen; T Tolstykh; J Stock
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

2.  Methylated C-terminal leucine residue of PP2A catalytic subunit is important for binding of regulatory Balpha subunit.

Authors:  J C Bryant; R S Westphal; B E Wadzinski
Journal:  Biochem J       Date:  1999-04-15       Impact factor: 3.857

3.  Brain protein phosphatase 2A: developmental regulation and distinct cellular and subcellular localization by B subunits.

Authors:  S Strack; J A Zaucha; F F Ebner; R J Colbran; B E Wadzinski
Journal:  J Comp Neurol       Date:  1998-03-23       Impact factor: 3.215

4.  Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A.

Authors:  E Sontag; V Nunbhakdi-Craig; G Lee; G S Bloom; M C Mumby
Journal:  Neuron       Date:  1996-12       Impact factor: 17.173

5.  Protein phosphatase 2A subunit assembly: the catalytic subunit carboxy terminus is important for binding cellular B subunit but not polyomavirus middle tumor antigen.

Authors:  E Ogris; D M Gibson; D C Pallas
Journal:  Oncogene       Date:  1997-08-18       Impact factor: 9.867

6.  Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis.

Authors:  Estelle Sontag; Christa Hladik; Lisa Montgomery; Ampa Luangpirom; Ingrid Mudrak; Egon Ogris; Charles L White
Journal:  J Neuropathol Exp Neurol       Date:  2004-10       Impact factor: 3.685

7.  Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau.

Authors:  S G Greenberg; P Davies; J D Schein; L I Binder
Journal:  J Biol Chem       Date:  1992-01-05       Impact factor: 5.157

8.  Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology.

Authors:  Estelle Sontag; Ampa Luangpirom; Christa Hladik; Ingrid Mudrak; Egon Ogris; Samuel Speciale; Charles L White
Journal:  J Neuropathol Exp Neurol       Date:  2004-04       Impact factor: 3.685

9.  A protein phosphatase methylesterase (PME-1) is one of several novel proteins stably associating with two inactive mutants of protein phosphatase 2A.

Authors:  E Ogris; X Du; K C Nelson; E K Mak; X X Yu; W S Lane; D C Pallas
Journal:  J Biol Chem       Date:  1999-05-14       Impact factor: 5.157

10.  Leucine carboxyl methyltransferase-1 is necessary for normal progression through mitosis in mammalian cells.

Authors:  Jocelyn A Lee; David C Pallas
Journal:  J Biol Chem       Date:  2007-08-27       Impact factor: 5.157

View more
  30 in total

1.  The protein phosphatase PP2A/Bα binds to the microtubule-associated proteins Tau and MAP2 at a motif also recognized by the kinase Fyn: implications for tauopathies.

Authors:  Jean-Marie Sontag; Viyada Nunbhakdi-Craig; Charles L White; Shelley Halpain; Estelle Sontag
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

Review 2.  Folate and Alzheimer: when time matters.

Authors:  Margareta Hinterberger; Peter Fischer
Journal:  J Neural Transm (Vienna)       Date:  2012-05-25       Impact factor: 3.575

Review 3.  Tau in neurodegenerative disease.

Authors:  Yong-Lei Gao; Nan Wang; Fu-Rong Sun; Xi-Peng Cao; Wei Zhang; Jin-Tai Yu
Journal:  Ann Transl Med       Date:  2018-05

4.  Folate/Vitamin B Alleviates Hyperhomocysteinemia-Induced Alzheimer-Like Pathologies in Rat Retina.

Authors:  Jing Guo; Shaozhou Ni; Qihang Li; Jian-Zhi Wang; Ying Yang
Journal:  Neurosci Bull       Date:  2018-09-28       Impact factor: 5.203

5.  The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment.

Authors:  Xiaochuan Wang; Julie Blanchard; Erik Kohlbrenner; Nathalie Clement; R Michael Linden; Aurelian Radu; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  FASEB J       Date:  2010-07-22       Impact factor: 5.191

6.  γ-Aminobutyric acid type A (GABAA) receptor activation modulates tau phosphorylation.

Authors:  Niko-Petteri Nykänen; Kai Kysenius; Prasanna Sakha; Päivi Tammela; Henri J Huttunen
Journal:  J Biol Chem       Date:  2012-01-10       Impact factor: 5.157

Review 7.  S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research.

Authors:  Anup Sharma; Patricia Gerbarg; Teodoro Bottiglieri; Lila Massoumi; Linda L Carpenter; Helen Lavretsky; Philip R Muskin; Richard P Brown; David Mischoulon
Journal:  J Clin Psychiatry       Date:  2017-06       Impact factor: 4.384

8.  Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain.

Authors:  Teodoro Bottiglieri; Erland Arning; Brandi Wasek; Viyada Nunbhakdi-Craig; Jean-Marie Sontag; Estelle Sontag
Journal:  J Neurosci       Date:  2012-07-04       Impact factor: 6.167

9.  PP2A methylation controls sensitivity and resistance to β-amyloid-induced cognitive and electrophysiological impairments.

Authors:  Russell E Nicholls; Jean-Marie Sontag; Hong Zhang; Agnieszka Staniszewski; Shijun Yan; Carla Y Kim; Michael Yim; Caitlin M Woodruff; Erland Arning; Brandi Wasek; Deqi Yin; Teodoro Bottiglieri; Estelle Sontag; Eric R Kandel; Ottavio Arancio
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-07       Impact factor: 11.205

Review 10.  All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.

Authors:  Jaya Sangodkar; Caroline C Farrington; Kimberly McClinch; Matthew D Galsky; David B Kastrinsky; Goutham Narla
Journal:  FEBS J       Date:  2015-11-14       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.